Nov 02, 2019
Drug | Mechanism | Route | Indication |
Afamelanotide | Melanocortin 1 receptor agonist | Subcutaneous | Phototoxicity in patients with erythropoietic protoporphyria |
Andexanet alpha | Bind to Factor Xa inhibitors | Intravenous | To reverse overdose of rivaroxaban and apixaban |
Apalutamide Darolutamide | Androgen receptor antagonist | Oral | Prostate carcinoma |
Avatrombopag Lusutrombopag | Thrombopoietin receptor agonist | Oral | Thrombocytopenia in patients with chronic liver disease |
Baloxavir marboxil | Inhibit viral replication by inhibiting Cap-dependent endonuclease activity of viral polymerase | Oral | Single dose treatment of Acute uncomplicated influenza |
Baricitinib | Janus Kinase inhibitor | Oral | Rheumatoid Arthritis |
Bremelanotide | Melanocortin receptor agonist | subcutaneous | Hypoactive sexual desire disorder in females |
Brexanolone | GABA-A modulator | Intravenous | Post partum depression |
Caplacizumab | vWF-directed antibody fragment | IV/SC | Thrombotic Thrombocytopenic Purpura |
Elagolix | GnRH antagonist | Oral | Pain associated with endometriosis |
Erenumab Fremanezumab Galcanezumab | Monoclonal antibody against CGRP | SC | Migraine prophylaxis |
Esketamine | Non-competitive NMDA antagonist | Intranasal | Treatment resistant depression |
Ibalizumab | MAb against CD4 | IV | HIV |
Inotersen | Antisense oligonucleotide against transthyretin mRNA | Subcutaneous | Polyneuropathy of hereditary transthyretin-mediated amyloidosis |
Istradefylline | Adenosine A2 receptor antagonist | Oral | Off episode in Parkinsonism |
Lasmiditan | 5HT1F agonist | Oral | Acute severe migraine |
Lofexidine | Alpha 2 agonist | Oral | To decrease opioid withdrawal symptoms |
Megalastat | Pharmacological chaperone for Alpha galactosidase | Oral | Fabry’s disease |
Moxidectin | Bind to Glutamate and GABA chloride channels | Oral | Onchocerciasis |
Netarsudil + Latanoprost | Netarsudil: Rho kinase inhibitor Latanoprost: PGF2 apha | Topical | Open angle glaucoma |
Patisiran | Small Interfering RNA based therapy against mutant transthyretin | Intravenous | Polyneuropathy in patients with transthyretin mediated amyloidosis |
Pitolisant | H3 antagonist/inverse agonist | Oral | Narcolepsy |
Pretomanid | Inhibit mycolic acid synthesis | Oral | For XDR and MDR TB (in combination with bedaquiline and linezolide) |
Ravulizumab | C5 Complement inhibitor | Intravenous | Paroxysomal Nocturnal Hemoglobinuria |
Romosozumab | MAb against sclerostin | Subcutaneous | Post-menopausal osteoporosis |
Selinexor | Selective inhibitor of nuclear export | Oral | Multiple myeloma Diffuse large B cell lymphoma |
Semaglutide | GLP-1 agonist | Oral | Type 2 diabetes mellitus |
Solriamfetol | DA and NA reuptake inhibitor | Oral | For excessive day time sleepiness in Obstructive sleep apnea and Narcolepsy |
Stiripentol | Increases GABAergic activity | Oral | Dravet Syndrome |
Tafenoquine | Free radical mediated killing of hypnozooites | Oral | Single dose radical cure of P. vivax malaria |
Tecovirimat | Inhibit formation of extracellular viral forms | Oral | Small pox |
Tenapanor | NHE-3 inhibitor | Oral | IBS with constipation |
Tolvaptan | Vasopressin V2 receptor antagonist | Oral | To slow kidney function decline in adult polycystic kidney disease |
Shweta has expertise in curating academic content and has assisted thousands of students in cracking various competitive exams and Owning their Dream.
Glaucoma is a leading cause of irreversible blindness worldwide, affecting an estimated 80 million people. Given its high prevalence, it is a fre...
The National Board of Examinations (NBE) has released the NEET PG 2023 scorecard. Candidates who appeared for the NEET PG 2023 examination can ch...
Seizures is one of the most crucial topics which you must study in-depth during your Emergency Medicine preparation. Questions from this topic ar...